Two important drugs, osimertinib and bevacizumab, have attracted considerable attention in the field of oncology.A third-generation EGFR tyrosine kinase inhibitor, osimertinib, has shown remarkable efficacy in the treatment of non-small cell lung cancer (NSCLC), especially in patients with EGFR mutations.A monoclonal antibody that targets vascular endothelial growth factor (VEGF), bevacizumab, has been widely used in the treatment of various cancers, including non-small cell lung cancer (NSCLC).The aim of this article is to offer a detailed review of osimertinib and bevacizumab, concentrating on their action mechanisms, clinical uses, and potential difficulties…
